低分子肝素治疗急性呼吸窘迫综合征疗效的Meta分析
该Meta分析检索PubMed、Cochrane Library、Web of Science、CNKI、CBM、VIP、万方等数据库至2020年9月,纳入12项RCT共623例急性肺损伤/ARDS患者,比较低分子肝素联合常规治疗与单纯常规治疗。结果显示低分子肝素组PaO2/FiO2升高(MD=72.08,95%CI 56.92-87.24,P<0.000 01),APACHE II(MD=-4.34,95%CI -5.73至-2.96,P<0.000 01)、IL-6(SMD=-2.13,95%CI -2.71至-1.56,P<0.000 01)、7天死亡率(RR=0.52,95%CI 0.30-0.90,P=0.02)和28天死亡率(RR=0.55,95%CI 0.34-0.90,P=0.02)均显著降低,APTT显著缩短(MD=-0.88,95%CI -1.51至-0.26,P=0.006);PT和PLT两组无统计学差异。结论认为低分子肝素可改善氧合、降低急性期死亡率和炎症反应,但可能增加出血风险。
要点
- 纳入12项RCT共623例ALI/ARDS患者,低分子肝素组较常规治疗组PaO2/FiO2升高(MD=72.08,95%CI 56.92-87.24,P<0.000 01)。
- 低分子肝素组7天死亡率(RR=0.52,95%CI 0.30-0.90,P=0.02)和28天死亡率(RR=0.55,95%CI 0.34-0.90,P=0.02)均显著低于常规治疗组。
- 低分子肝素组APACHE II(MD=-4.34,95%CI -5.73至-2.96,P<0.000 01)和IL-6(SMD=-2.13,95%CI -2.71至-1.56,P<0.000 01)显著降低。
- 低分子肝素组APTT显著缩短(MD=-0.88,95%CI -1.51至-0.26,P=0.006),PT(P=0.28)和PLT(P=0.99)两组无统计学差异。
- 对11篇纳入文献的PaO2/FiO2进行漏斗图分析提示可能存在发表偏倚。
适用人群与场景
- 急性肺损伤/急性呼吸窘迫综合征(ALI/ARDS)患者,纳入12项随机对照试验共623例。
处置流程与药物剂量
- 常规治疗组给予常规治疗;低分子肝素组在常规治疗基础上给予低分子肝素(原文未写明具体剂量、给药途径和频次)。
研究设计与关键结果
- 研究类型为Meta分析,纳入12项RCT共623例ALI/ARDS患者,比较低分子肝素联合常规治疗与单纯常规治疗。
- 低分子肝素组较常规治疗组PaO2/FiO2升高(MD=72.08,95%CI 56.92-87.24,P<0.000 01)。
- 低分子肝素组APACHE II较常规治疗组降低(MD=-4.34,95%CI -5.73至-2.96,P<0.000 01)。
- 低分子肝素组IL-6较常规治疗组降低(SMD=-2.13,95%CI -2.71至-1.56,P<0.000 01)。
- 低分子肝素组7天死亡率低于常规治疗组(RR=0.52,95%CI 0.30-0.90,P=0.02)。
- 低分子肝素组28天死亡率低于常规治疗组(RR=0.55,95%CI 0.34-0.90,P=0.02)。
- 低分子肝素组APTT较常规治疗组显著缩短(MD=-0.88,95%CI -1.51至-0.26,P=0.006)。
- PT两组无统计学差异(MD=-0.44,95%CI -1.23至0.36,P=0.28);PLT两组无统计学差异(MD=-0.08,95%CI -18.81至18.65,P=0.99)。
证据类型、等级与局限
- 证据类型:Meta分析,纳入12项随机对照试验。
- 采用Cochrane协作网评价工具评价文献质量。
- 局限:对11篇纳入文献的PaO2/FiO2进行漏斗图分析提示可能存在发表偏倚;原文未报告其他局限性。
对床旁实践的改变
- 作者认为低分子肝素可改善ARDS患者氧合低下、降低急性期死亡率及炎症反应,但可能增加ARDS患者出血风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To observe the clinical effect of low molecular weight heparin on the curative effect of acute respiratory distress syndrome (ARDS) patients through a systematic evaluation method.
METHODS: Databases such as PubMed, Cochrane Library database, Web of Science, CNKI, China Biological Medical Literature Database (CBM), VIP, Wanfang database were searched to retrieve randomized controlled trials (RCTs) on low molecular weight heparin and conventional treatment on the efficacy and prognosis of patients with acute lung injury (ALI)/ARDS from the establishment of the database to September 2020. The conventional treatment group was given conventional treatment, and the low molecular heparin group was given low molecular heparin based on conventional treatment. Outcome indicators were oxygenation index (PaO2/FiO2), acute physiology and chronic health evaluation II (APACHE II), activated partial thromboplastin time (APTT), prothrombin time (PT), platelet count (PLT), interleukin-6 (IL-6) and the mortality at 7 days and 28 days. The literature was screened according to the proposed inclusion and exclusion criteria; the Cochrane collaboration evaluation tool was used to evaluate the quality of literature; Meta analysis used RevMan 5.3 software to perform funnel plot analysis on the outcome indicators of the included ≥ 11 literatures, and to evaluate the publication bias.
RESULTS: A total of 12 RCTs and 623 patients were included. The results of Meta analysis showed that PaO2/FiO2 increased in the low molecular weight heparin group compared with the conventional treatment group [mean difference (MD) = 72.08, 95% confidence interval (95%CI) was 56.92-87.24, P < 0.000 01], APACHE II (MD = -4.34, 95%CI was -5.73 to -2.96, P < 0.000 01), IL-6 [standardized mean difference (SMD) = -2.13, 95%CI was -2.71 to -1.56, P < 0.000 01] and 7-day mortality [relative risk (RR) = 0.52, 95%CI was 0.30-0.90, P = 0.02] and 28-day mortality (RR = 0.55, 95%CI was 0.34-0.90, P = 0.02) were significantly reduced, APTT was significantly shortened (MD = -0.88, 95%CI was -1.51 to -0.26, P = 0.006); but PT (MD = -0.44, 95%CI was -1.23 to 0.36, P = 0.28) and PLT (MD = -0.08, 95%CI was -18.81 to 18.65, P = 0.99) between the two groups had no statistically significant differences. A funnel chart analysis of PaO2/FiO2 with 11 included papers showed that there might be publication bias.
CONCLUSIONS: Low molecular weight heparin can improve the poor oxygenation of ARDS patients, reduce the mortality of ARDS patients in the acute stage and the inflammatory reaction, but it may increase the bleeding risk of ARDS patients.
参考来源
- Jiang X, Feng R, Liu J, et al. [Meta-analysis of the curative effect of low molecular weight heparin on acute respiratory distress syndrome]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 33541500. doi:10.3760/cma.j.cn121430-20201019-01426
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。